Oxford Biomedica has signed an 18 month supply agreement with AstraZeneca for the large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222.
The companies may extend the supply period for AZD1222 by a further 18 months into 2022 and 2023 by mutual agreement.
Under the terms of this initial agreement, AstraZeneca will pay Oxford Biomedica £15 million upfront as a capacity reservation fee.
Subject to satisfactory scale up of manufacturing capacity and continuation of the vaccine programme, Oxford Biomedica expects to receive additional revenue in excess of £35 million plus certain materials costs for the manufacture of multiple large-scale batches of AZD1222 until the end of 2021.
As part of the agreement, Oxford Biomedica will reserve capacity for AstraZeneca in up to three manufacturing suites in the Group’s new 7,800 m2 commercial manufacturing centre, Oxbox, for an initial 18-month period.
This new GMP facility is suitable for manufacturing viral vectored vaccines and gene therapy vectors up to 1,000 litre scale.
As part of Oxford Biomedica’s previously announced partnership with the UK’s Vaccine Manufacturing Innovation Centre (VMIC) two new manufacturing suites within Oxbox will become operational in the next two months, significantly earlier than originally planned by the Group.
This agreement builds on the supply agreement between the companies announced on 28th May, which related exclusively to manufacture of AZD1222 at 200L scale and associated process development.